"Wegovy: FDA Approves Weight-Loss Drug for Heart Health Benefits"
TL;DR Summary
The FDA has approved the addition of cardiovascular benefits to the weight-loss drug Wegovy's label, making it the first of its kind to be cleared to reduce the risk of heart attack, stroke, or heart-related death in high-risk individuals. This label expansion may improve insurance coverage for the drug, which costs over $1,300 per month, and is based on a 17,000-patient study showing a 20% lower risk of cardiac events for those taking Wegovy. The drug is indicated for people with obesity or overweight and at least one weight-related health condition, and its manufacturer, Novo Nordisk, is working to increase manufacturing capacity to meet demand.
Topics:health#cardiovascular-benefits#fda-approval#health-medicine#novo-nordisk#obesity#weight-loss-drug
- Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update CNN
- Novo Nordisk's Wegovy wins FDA approval for cutting heart disease risks, in move that could expand insurance coverage CNBC
- FDA approves Wegovy to reduce heart attack and stroke risk NBC News
- Weight loss drug Wegovy approved for heart health The Hill
- Novo's obesity superstar Wegovy wins FDA nod to cut cardio risks in key label expansion FiercePharma
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
83%
611 → 105 words
Want the full story? Read the original article
Read on CNN